Clinical Use of Human Prothrombin Complexes

Tullis, James L.; Melin, M.; Jurigian, Paul

doi:10.1056/nejm196509232731301

Cited by 66 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FIGuRE 5 Distribution of plasma radioactivity in a normal subject (L.S.) 22 travascular distribution.…”

Section: Resultsmentioning

confidence: 99%

“…Studies of the in vivo behavior of this zymogen in man have been limited to measurements of the decay of biological activity after infusions of large amounts of plasma or prothrombin concentrates (1)(2)(3)(4)(5), or after the administration of large doses of a hypoprothrombinemic agent (6)(7)(8)(9)(10). Such During the latter part of this study Dr. Martinez was the recipient of a Special Fellowship, 1 F03 HE-39516, from the National Institutes of Health.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human prothrombin metabolism in normal man and in hypocoagulable subjects

Shapiro¹,

Martinez²

1969

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T The metabolism of human prothrombin labeled with radioactive iodine was studied in seven normal subjects and four hemophilic patients. Results in the normal subjects were: plasma volume, 37.6 ±3.8 ml/kg; plasma prothrombin concentration, 303 ±40 U/ml (0.153 + 0.02 mg/ml); prothrombin half-life, 2.81 +0.51 days; total plasma prothrombin pool, 5.72 +0.62 mg/kg, representing 64.1 ±9.1% of total body prothrombin; fractional catabolic rate, 42.5 +±12.4% of the plasma pool per day; prothrombin synthesis rate, 2.43 + 0.76 mg/kg per day. Results in the hemophilic patients did not differ significantly from normal. Circulating products of prothrombin activation could not be demonstrated in normal individuals or hemophilic subjects. The data suggest that continuous physiologic activation of the blood coagulation mechanism plays only a small part, if any, in the normal catabolism of prothrombin.

show abstract

“…FIGuRE 5 Distribution of plasma radioactivity in a normal subject (L.S.) 22 travascular distribution.…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Human prothrombin metabolism in normal man and in hypocoagulable subjects

Shapiro¹,

Martinez²

1969

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…4 When the level of zymogen Factor VII is low, or the amount of Factor VII to Factor VIla decreased, one would expect the dampening effect of Factor VII to be diminished. It is tempting to speculate that the loss of this inhibitory effect of zymogen Factor VII might contribute to the thrombotic complications associated with congenital Factor VII deficiency (48)(49)(50), loading dose coumarin therapy (51,52), and infusion of prothrombin complex concentrates, which may contain high levels of activated Factor VII (46,(53)(54)(55)(56)(57)(58)(59)(60)(61)(62).…”

Section: Methodsmentioning

confidence: 99%

Binding of human factor VII and VIIa to monocytes.

Broze¹

1982

J. Clin. Invest.

180

View full text Add to dashboard Cite

show abstract

“…Factor IX Concentrates 'Preconativ' is manufactured by AB Kabi, Stockholm, with a slight modifica tion of the method originally described by Tullis et al [17]. 'Konyne' (called 'Hemoplex' in 1969) is manufactured by Cutter Laboratories, Berkeley, Calif., as described by Hoag et al [7].…”

Section: Methodsmentioning

confidence: 99%

Incidence of Viral Hepatitis after Administration of Factor IX Concentrates

Iwarson¹,

Kjellman²,

Teger‐Nilsson³

1976

Vox Sanguinis

View full text Add to dashboard Cite

A high frequency of viral hepatitis has been reported after treatment with the human factor IX concentrate ‘Konyne’. Clinical trials with ‘Konyne’ and a similar factor IX concentrate, called ‘Preconativ’, was started in Sweden 1969. During the first 2 years, 26 patients were treated with either one or both preparations. Nine patients developed viral hepatitis within 6 months after treatment. ‘Preconativ’ alone was introduced on the Swedish market in 1971. During the period 1971-1974, another 26 hemophiliacs were treated but only two cases of hepatitis have occurred. Selection of donors and screening for hepatitis B surface antigen in donor blood used for the manufacturing of ‘Preconativ’, might be contributing factors to this low hepatitis incidence.

show abstract

Clinical Use of Human Prothrombin Complexes

Cited by 66 publications

References 11 publications

Human prothrombin metabolism in normal man and in hypocoagulable subjects

Human prothrombin metabolism in normal man and in hypocoagulable subjects

Binding of human factor VII and VIIa to monocytes.

Incidence of Viral Hepatitis after Administration of Factor IX Concentrates

Contact Info

Product

Resources

About